

Contents

Authors	xv
Preface	xix

Section I. Prevention of Cardiovascular Disease

1. Lipid Disorders 1

<i>Mohamad Alkhouli, MD, Harish Jarrett, MBChB, & Sara Sirna, MD</i>	
General Considerations	1
Lipoproteins and Apolipoproteins	1
Metabolism	1
Atherosclerosis	3
Clinical Findings	3
Secondary Causes of Dyslipidemia	3
Diagnosis	4
Treatment	4
LDL Goals	4
HDL Goals	5
Hypertriglyceridemia and Non-HDL Goals	5
Nonpharmacologic Treatment	6
Pharmacologic Treatment	6
Treatment in Specific Patient Populations	7
Prognosis	8

2. Systemic Hypertension 9

<i>Wanpen Vongpatanasin, MD</i>	
General Considerations	9
Pathophysiology & Etiology	9
Clinical Findings	10
BP Measurement	10
Symptoms & Signs	10
Physical Examination	11
Diagnostic Studies	11
Differential Diagnosis	11
Obstructive Sleep Apnea	11
Primary Aldosteronism	11
Renal Parenchymal Disease	12
Renovascular Hypertension	12
Pheochromocytoma	12
Treatment	12
Lifestyle Modification	12
Pharmacologic Intervention	13
Management of Uncomplicated Hypertension	16
Management of Hypertensive Crisis	17
Management of Resistant Hypertension	18
Prognosis	19

3. Antiplatelet Therapy 22

<i>Ashvarya Mangla, MD & Saurabh Gupta, MD</i>	
General Considerations	22
Role of Platelets in Thrombosis	22
Classification of Antiplatelet Drugs	22
Cyclooxygenase Inhibitors: Aspirin	22
P ₂ Y ₁₂ Receptor Blockers	23
GP II _b III _a Inhibitors	24
Phosphodiesterase Inhibitors	24
Treatment	25
Special Issues with Antiplatelet Therapy	25
Special Populations	25

4. Long-Term Anticoagulation for Cardiac Conditions 27

<i>Richard D. Taylor, MD & Richard W. Asinger, MD</i>	
General Considerations	27
Anticoagulants	27
Risks of Anticoagulant Therapy	29
Pathophysiology & Etiology	30
Pathogenesis of Intravascular Thrombi	30
Embolization of Thrombi	30
Diagnostic Studies	31
Treatment of Cardiac Conditions Requiring	
Anticoagulation	34
Atrial Fibrillation	34
Native Valvular Heart Disease	39
Prosthetic Heart Valves	40
Left Ventricular Thrombus	41
Aortic Atheroma	43
Paradoxical Emboli Associated with Patent Foramen Ovale	43
Pacemakers, Implantable Cardioverter-Defibrillators, and Other Intracardiac Devices	43
Special Considerations	44
Pregnancy	44
Interruption of Anticoagulation for Surgery and Invasive Procedures	45

5. Approach to Cardiac Disease Diagnosis 47

<i>Michael H. Crawford, MD</i>	
General Considerations	47
Common Symptoms	47
History	48

Physical Findings	49
Physical Examination	49
Diagnostic Studies	53

Section II. Ischemic Heart Disease

6. Chronic Ischemic Heart Disease 59

Michael H. Crawford, MD

General Considerations	59
Pathophysiology & Etiology	59
Clinical Findings	60
Risk Factors	60
Symptoms & Signs	60
Physical Examination	61
Laboratory Findings	61
Diagnostic Studies	61
Choosing a Diagnostic Approach	63
Treatment	64
General Approach	64
Pharmacologic Therapy	65
Revascularization	68
Selection of Therapy	69
Prognosis	71

7. Unstable Angina/Non-ST Elevation Myocardial Infarction 72

Kuang-YuhChyu, MD, PhD & Prediman K. Shah, MD

General Considerations	72
Background	72
Pathophysiology	72
Clinical Findings	72
Symptoms	72
Physical Examination	73
Diagnostic Studies	73
Differential Diagnosis	74
Acute Myocardial Infarction	75
Acute Aortic Dissection	75
Acute Pericarditis	75
Acute Pulmonary Embolism	75
Gastrointestinal Causes of Pain	75
Other Causes of Chest Pain	75
Treatment	75
Initial Management	75
Definitive Management	81
Prognosis	81

8. Acute Myocardial Infarction 83

Andrew J. Boyle, MBBS, PhD

General Considerations	83
Pathophysiology & Etiology	83
Clinical Findings	84

Symptoms & Signs	84
Physical Examination	85
Diagnostic Studies	85
Treatment	88
Prehospital Management	88
Emergency Department Therapy	88
Reperfusion Therapy	90
In-Hospital Management	90
Primary PCI Versus Fibrinolysis	92
Fibrinolytic Agents	93
Adverse Effects of Fibrinolytic Therapy	94
Complications of Myocardial Infarction	95
Cardiogenic Shock	95
Congestive Heart Failure	96
Acute Mitral Valve Regurgitation	96
Acute Ventricular Septal Rupture	97
Cardiac Rupture	97
Recurrent Ischemia	97
Pericarditis	97
Conduction Disturbances	98
Other Arrhythmias	99
Mural Thrombi	100
Aneurysm and Pseudo-Aneurysms	100
Right Ventricular Infarction	100
Prognosis, Risk Stratification, & Management	101
Risk Predictors	101
Risk Assessment	101
Risk Management	102

9. Cardiogenic Shock 104

Edward McNulty, MD

General Considerations	104
Definition	104
Etiology	104
Pathogenesis	105
Cardiogenic Shock after Acute MI	105
Mechanical Complications of Acute MI	105
Right Ventricular Infarction	107
Arrhythmias	107
Other Causes of Cardiogenic Shock	107
Clinical Findings	107
History	107
Physical Examination	107
Laboratory Findings	108
Diagnostic Studies	108
Left Heart (Cardiac) Catheterization	109
Treatment	109
Acute Myocardial Infarction	109
Mechanical Complications	111
Right Ventricular Infarction	112
Arrhythmias	112
Prognosis	112

10. Evaluation & Treatment of the Perioperative Patient 113

Sanjiv J. Shah, MD & Michael H. Crawford, MD

Preoperative Risk Assessment	113
Algorithms	113
Intermediate-Risk Patients	114
Understanding Cardiac Complications	115
Treatment to Reduce Perioperative Risk	115
β -Blockers	115
Statins	115
Clonidine	115
Calcium Channel Blockers	116
Aspirin	116
Deep Venous Thrombosis Prophylaxis	116
Endocarditis Prophylaxis	116
Perioperative Medication Management	116
Prophylactic Coronary Revascularization	117
Special Populations	118
Liver Transplantation	118
Aortic Stenosis	118
Heart Failure	119
Pulmonary Hypertension	119
Pacemakers, Defibrillators, & Atrial Fibrillation	119

Section III. Arrhythmias

11. Supraventricular Tachycardias 120

Byron K. Lee, MD & Peter R. Kowey, MD

General Considerations	120
Pathophysiology & Etiology	120
General Diagnostic Approach	123
Sinus Tachycardia & Sinus Node Reentry	123
Sinus Tachycardia	123
General Considerations	124
Treatment	124
Sinus Node Reentry	124
General Considerations	124
Treatment	124
Atrial Flutter	124
General Considerations	125
Pathophysiology	125
Clinical Findings	125
Prevention	125
Treatment	125
Conversion	125
Rate Control	126
Catheter Ablation and Other Modalities	126
Stroke Prophylaxis	126
Multifocal Atrial Tachycardia	126
General Considerations	126
Treatment	126
Prognosis	127

Atrial Tachycardia	127
General Considerations	127
Treatment	128
Pharmacologic Therapy	128
Ablation	128
Atrioventricular Nodal Reentrant Tachycardia	128
General Considerations	128
Pathophysiology	128
Prevention	129
Treatment	129
Vagal Maneuvers	129
Pharmacologic Therapy	129
Catheter Ablation	129
Junctional Tachycardia (Accelerated AV Junctional Rhythm)	131
General Considerations	131
Clinical Findings	131
Treatment	131
Atrioventricular Reciprocating Tachycardia	131
Bypass Tracts & the Wolff-Parkinson-White Syndrome	131
General Considerations	131
Epidemiology	132
Pathophysiology	132
Anatomy	132
Cardiac Electrical Conduction	134
Mechanism	136
Treatment	137
Vagal Maneuvers	137
Pharmacologic Therapy	137
Radiofrequency Catheter Ablation Therapy	138
Surgical Ablation Therapy	139
Other Bypass Tracts	139
Differentiation of Wide QRS Complex Tachycardias	139
Other Supraventricular Arrhythmias	140
Sinus Node Arrhythmia	140
General Considerations	140
Treatment	140
Wandering Atrial Pacemaker	140
General Considerations	140
Treatment	140

12. Atrial Fibrillation 141

Melvin M. Scheinman, MD

General Considerations	141
Clinical Findings	141
Symptoms & Signs	141
Initial Evaluation	141
Differential Diagnosis	142
Treatment	142
Rate Control	143

Long-Term Antiarrhythmic Therapy and Elective Cardioversion	143
Antiarrhythmic Drug Therapy for Atrial Fibrillation	143
Chemical Cardioversion	145
Other Drugs for Chemical Cardioversion	145
Anticoagulant Therapy	145
Direct-Current Cardioversion	147
Long-Term Approach	148
Nonpharmacologic Treatment of Atrial Fibrillation	149
Prognosis	149

13. Ventricular Tachycardia 150

<i>Nitish Badhwar, MD</i>	
Diagnostic Issues	150
Underdiagnosis	150
Misdiagnosis	150
Diagnostic Approach to the Patient with Wide QRS Complex Tachycardia	151
Atrioventricular Relationship	153
QRS Complex Duration	153
Specific QRS Morphology	153
QRS Complex Axis	155
History, Physical Examination, and 12-Lead ECG	155
Classifications of Ventricular Tachycardia	156
Ventricular Tachycardia Associated with Structural Heart Disease	156
Monomorphic Ventricular Tachycardia in Association with Chronic Coronary Artery Disease	156
Monomorphic Ventricular Tachycardia in Association with Idiopathic Dilated Cardiomyopathy	157
Monomorphic Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathy	157
Monomorphic Ventricular Tachycardia in Patients with Congenital Heart Disease	158
Monomorphic Ventricular Tachycardia in Other Forms of Structural Heart Disease	158
Ventricular Tachycardia Not Associated with Structural Heart Disease	158
Idiopathic Left Ventricular Tachycardia or Fascicular Ventricular Tachycardia	158
Outflow Tract Ventricular Tachycardia	159
Annular Ventricular Tachycardia	160
Diagnostic Studies	160
Management of Monomorphic Ventricular Tachycardia	161
Immediate Termination	162
Prevention	163

Pharmacologic Therapy	163
Nonpharmacologic Therapy	163
Polymorphic Ventricular Tachycardia	164
Polymorphic Ventricular Tachycardia in the Setting of Prolonged QT Interval	164
Clinical Findings	164
Management	165
Polymorphic Ventricular Tachycardia with a Normal QT Interval	166
Prognosis	167

14. Conduction Disorders & Cardiac Pacing 168

<i>Richard H. Hongo, MD & Nora F. Goldschlager, MD</i>	
General Considerations	168
Pathophysiology & Etiology	168
Sinus Node Dysfunction	168
Atrioventricular Block	169
Clinical Findings	170
Symptoms & Signs	170
Physical Examination	174
Diagnostic Studies	175
Treatment	181
Cardiac Pacing	184
Pacing System Malfunctions	196
Assessment of Pacing System Function	197

15. Sudden Cardiac Death 200

<i>Andrew E. Darby, MD & John P. DiMarco, MD, PhD</i>	
General Considerations	200
Pathophysiology & Etiology	200
Coronary Artery Disease	201
Hypertrophic Cardiomyopathy	202
Nonischemic Dilated Cardiomyopathy	202
Other Cardiac Diseases	202
Inherited Arrhythmia Syndromes	202
Drug-Induced Arrhythmias	203
Other Arrhythmias	203
Management of Cardiac Arrest:	
Initial Resuscitation	204
Management of Cardiac Arrest	
Survivors: In-Hospital Phase	204
Complications of Resuscitation	204
Diagnostic Studies	205
Treatment of Cardiac Arrest Survivors	207
Antiarrhythmic Drug Therapy	207
Revascularization	208
Surgical or Catheter Ablation	208
Implantable Cardioverter-Defibrillators	208
Identification of Patients at Risk	210
Risk Assessment Studies	210
Primary Prevention of Sudden Death	211

16. Syncope 213*Michael H. Crawford, MD*

General Considerations	213
Pathophysiology & Etiology	213
Cardiac Causes	213
Neurocardiogenic Causes	214
Orthostatic Hypotension	215
Clinical Findings	217
History & Physical Examination	217
Noninvasive Diagnostic Studies	218
Invasive Electrophysiology Studies	220
Differential Diagnosis	221
Seizure	221
Metabolic Disorders and Hypoxia	221
Cerebral Vascular Insufficiency and Extracranial Vascular Disease	221
Psychiatric Disorders with Hyperventilation and Pseudoseizure	221
Treatment	222
Pharmacologic and Nonpharmacologic	222
Electrophysiologic Therapies	223
Prognosis	223

Section IV. Valvular Disease**17. Aortic Stenosis 225***Steven J. Lester, MD & Amr E. Abbas, MD*

General Considerations & Etiology	225
Clinical Findings	225
History	225
Physical Examination	227
Diagnostic Studies	227
Diagnostic Dilemmas: Area Gradient Mismatch	231
Low EF Area-Gradient Mismatch	231
Normal EF Area-Gradient Mismatch	232
Reverse Area-Gradient Mismatch	232
Treatment	232
Medical Therapy	232
Valve Replacement	233
Special Circumstances	235
Low EF Area-Gradient Mismatch (LF/LG Aortic Stenosis)	235
Normal EF Area-Gradient Mismatch (PLF/LG Aortic Stenosis)	236
Prognosis	236

18. Aortic Regurgitation 237*Michael H. Crawford, MD*

Etiology	237
Pathophysiology	237
Chronic Aortic Regurgitation	237
Acute Aortic Regurgitation	237

Clinical Findings	238
Symptoms & Signs	238
Laboratory Findings	239
Diagnostic Studies	239
Treatment	244
Acute Aortic Regurgitation	244
Chronic Aortic Regurgitation	245
Prognosis	247

19. Mitral Stenosis 248*D. Elizabeth Le, MD*

General Considerations	248
Anatomy	248
Etiology	249
Pathophysiology	249
Clinical Findings	252
Symptoms & Signs	252
Physical Examination	253
Diagnostic Studies	253
Electrocardiography	253
Chest Radiography	253
Echocardiography	254
Exercise-Stress Echocardiography	258
Cardiac Computed Tomography and Magnetic Resonance Imaging	259
Cardiac Catheterization	259
Differential Diagnosis	259
Treatment	259
Lifestyle Modifications	259
Pharmacologic Therapy	259
Interventional Therapy	260
Prognosis	262

20. Mitral Regurgitation 263*Michael H. Crawford, MD*

General Considerations	263
Clinical Findings	264
Symptoms & Signs	264
Physical Examination	264
Diagnostic Studies	266
Differential Diagnosis	268
Treatment	269
Pharmacologic Therapy	269
Surgical Treatment	269
Prognosis	271

21. Tricuspid & Pulmonic Valve Disease 272*Brian D. Hoit, MD & Michael H. Crawford, MD*

Tricuspid Valve Disease	272
General Considerations	272
Pathophysiology & Etiology	272
Tricuspid Regurgitation	272
Tricuspid Stenosis	274

Clinical Findings	274
Symptoms & Signs	274
Physical Examination	274
Diagnostic Studies	277
Treatment	280
Medical	280
Surgical	280
Prognosis	282
Pulmonic Valve Disease	282
General Considerations	282
Pathophysiology & Etiology	282
Pulmonic Regurgitation	283
Pulmonic Stenosis	283
Clinical Findings	283
Symptoms & Signs	283
Physical Examination	283
Diagnostic Studies	284
Treatment	284
Prognosis	284

22. Infective Endocarditis 285

Michael H. Crawford, MD

General Considerations	285
Pathophysiology & Etiology	285
Cardiac Infection—Vegetations	285
Extracardiac Disease	286
Clinical Syndromes	286
Clinical Findings	290
Diagnostic Criteria	290
Symptoms & Signs	291
Physical Examination	291
Diagnostic Studies	292
Management	295
Initial Decisions	295
Antibiotic Therapy	295
Management of Complications	296
Management of High-Risk Endocarditis	298
Surgery	299
Follow-Up after Endocarditis	299

Section V. Cardiomyopathy & Heart Failure

23. Hypertrophic Cardiomyopathy 301

Karthik Ananthasubramaniam, MD

General Considerations	301
Definition & Prevalence	301
Genetics & Histopathology	301
Phenotype of Hypertrophic Cardiomyopathy	302
Pathophysiology	302
Diastolic Dysfunction	302
Outflow Obstruction	303

Mitral Regurgitation	304
Myocardial Ischemia	305
Abnormal Autonomic Tone	305
Clinical Findings	305
Physical Examination	305
Diagnostic Tests	306
Diagnostic Considerations in Hypertrophic Cardiomyopathy Variants	310
Management	311
Pharmacologic Strategies	311
Nonpharmacologic Therapies	312
Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy	313
Hypertrophic Cardiomyopathy and Athlete's Heart	314
Special Considerations in Hypertrophic Cardiomyopathy	314

24. Restrictive Cardiomyopathy 315

James A. Goldstein, MD

Overview	315
Pertinent Aspects of Normal Hemodynamics	315
Pathophysiology	316
Clinical Findings	317
Etiologies	318
Myocardial Disorders	318
Endomyocardial Disease	319
Differentiating Restrictive Cardiomyopathy from Other Disorders	320
Clinical Algorithms to Differentiate Constriction from Restriction	321
Treatment	322
Prognosis	322

25. Myocarditis 323

Michael H. Crawford, MD

General Considerations	323
Pathophysiology	323
Clinical Findings	324
Symptoms & Signs	324
Physical Examination	325
Diagnostic Studies	325
Treatment	327
Prognosis	328
Specific Forms of Myocarditis	328
Chagas Disease, or American Trypanosomiasis	328
Human Immunodeficiency Virus	328
Toxoplasmosis	329
Cytomegalovirus	329
Lyme Myocarditis	329
Giant Cell Myocarditis	329
Sarcoidosis	329

26. Heart Failure with Reduced Ejection Fraction 331

Liviu Klein, MD, MS

General Considerations	331
Pathophysiology	332
Clinical Findings	334
Symptoms & Signs	334
Physical Examination	334
Laboratory Testing	335
Diagnostic Studies	337
Treatment	338
Prevention	338
Nonpharmacologic Treatment	338
Pharmacologic Treatment:	
Life-Saving Therapies	340
Pharmacologic Treatment:	
Symptomatic Therapies	342
Pharmacologic Treatment:	
Other Therapies	343
Pharmacologic Treatment:	
Specific Therapies in Hospitalized Patients	345
Electrical Treatment	345
Surgical Treatment	345
Disease Management	346
Prognosis	346

27. Heart Failure with Preserved Ejection Fraction 348

Sanjiv J. Shah, MD

General Considerations	348
Pathophysiology	348
Diastolic Dysfunction	349
Left Ventricular Enlargement and Increased Intravascular Volume	349
Abnormal Ventricular-Arterial Coupling	349
Right Heart Failure	350
Chronotropic incompetence	350
Left Ventricular Hypertrophy	350
Coronary Artery Disease	350
Clinical Findings	351
Risk Factors	351
Symptoms & Signs	351
Diagnostic Studies	352
Differential Diagnosis	354
Prevention	355
Treatment	356
Nonpharmacologic Therapy	356
Pharmacologic Therapy	356
Prognosis	359

28. Pericardial Diseases 361

Massimo Imazio, MD

General Considerations	361
Normal Pericardial Anatomy & Physiology	361
Pericardial Pressure & Normal Function	361
Etiology & Pathogenesis	361
Infectious Pathogens	361
Iatrogenic Causes	362
Connective Tissue Disorders	363
Other Causes	363
Acute Pericarditis	364
General Considerations	365
Clinical Findings	365
Symptoms & Signs	365
Physical Examination	365
Diagnostic Studies	365
Treatment	366
Pericardial Effusion	368
General Considerations	368
Clinical Findings	369
Symptoms & Signs	369
Physical Examination	369
Diagnostic Studies	369
Treatment	370
Cardiac Tamponade	371
General Considerations	371
Clinical Findings	371
Symptoms & Signs	371
Diagnostic Studies	372
Treatment	373
Constrictive Pericarditis	373
General Considerations	373
Clinical Findings	374
Symptoms & Signs	374
Physical Examination	374
Diagnostic Studies	374
Differential Diagnosis	376
Treatment	377
Effusive-Constrictive Pericarditis	378

29. Pulmonary Embolic Disease 379

Sandeep A. Saha, MBBS & Rajni K. Rao, MD

General Considerations	379
Etiology	379
Thrombophilia	379
Women's Health	380
Clinical Findings	380
Symptoms & Signs	381
Diagnostic Studies	382
Prevention	386
Nonpharmacologic Prevention	386
Pharmacologic Prevention	386
Future Directions	387

Risk Stratification	388
Treatment	389
Heparin	389
Low-Molecular-Weight Heparin	390
Fondaparinux	390
Thrombolysis	391
Embolectomy	392
Inferior Vena Cava Filters	392
Warfarin	393
Newer Anticoagulants	393
Adjunctive Measures	393
Duration of Treatment of Acute Pulmonary Embolism	393
Venous Thromboembolism in Pregnancy	394
Counseling	394

30. Pulmonary Hypertension 396

*Christopher F. Barnett, MD, MPH &
Teresa De Marco, MD*

General Considerations	396
Classification & Pathogenesis	396
Pulmonary Arterial Hypertension	397
Pulmonary Hypertension with Left-Sided Heart Disease	400
Pulmonary Hypertension Associated with Lung Diseases and Hypoxemia	401
Pulmonary Hypertension due to Chronic Thrombotic or Embolic Diseases	401
Miscellaneous	401
Pathophysiologic Consequences of Pulmonary Hypertension	401
Clinical Findings	403
Symptoms & Signs	403
Physical Examination	403
Diagnostic Studies	403
Differential Diagnosis	408
Treatment	408
Pulmonary Arterial Hypertension	408
Pulmonary Hypertension with Left-Sided Heart Disease	414
Pulmonary Hypertension Associated with Lung Disease or Hypoxemia	414
Pulmonary Hypertension due to Chronic Thrombotic or Embolic Disease	415
Prognosis	415

31. Congenital Heart Disease in Adults 416

Ian S. Harris, MD & Elyse Foster, MD

General Considerations	416
Acyanotic Congenital Heart Disease	416
Congenital Aortic Valvular Disease	417
General Considerations	417
Clinical Findings	417

Symptoms & Signs	417
Diagnostic Studies	417
Differential Diagnosis	418
Prognosis & Treatment	419
Pulmonary Valve Stenosis	420
General Considerations	420
Clinical Findings	420
Symptoms & Signs	420
Diagnostic Studies	420
Prognosis & Treatment	422
Atrial Septal Defect	423
General Considerations	423
Clinical Findings	424
Symptoms & Signs	424
Diagnostic Studies	424
Prognosis & Treatment	425
Ventricular Septal Defects	427
General Considerations	427
Clinical Findings	428
Symptoms & Signs	428
Diagnostic Studies	428
Prognosis & Treatment	429
Patent Ductus Arteriosus	430
General Considerations	430
Clinical Findings	431
Symptoms & Signs	431
Diagnostic Studies	431
Prognosis & Treatment	431
Coarctation of the Aorta	432
General Considerations	432
Clinical Findings	432
Symptoms & Signs	432
Diagnostic Studies	433
Prognosis & Treatment	433
Ebstein Anomaly	435
General Considerations	435
Clinical Findings	436
Symptoms & Signs	436
Diagnostic Studies	436
Prognosis & Treatment	436
Congenitally Corrected Transposition of the Great Arteries	437
General Considerations	438
Clinical Findings	439
Symptoms & Signs	439
Diagnostic Studies	439
Prognosis & Treatment	440
Other Acyanotic Congenital Defects	441
Cyanotic Congenital Heart Disease	442
Tetralogy of Fallot & Pulmonary Atresia with Ventricular Septal Defect	443
General Considerations	443
Clinical Findings	443
Symptoms & Signs	443
Diagnostic Studies	443
Prognosis & Treatment	445

Eisenmenger Syndrome	446
General Considerations	446
Clinical Findings	446
Symptoms & Signs	446
Diagnostic Studies	446
Prognosis & Treatment	449
Transposition of the Great Arteries	449
General Considerations	449
Clinical Findings	449
Symptoms & Signs	449
Diagnostic Studies	450
Prognosis & Treatment	451
Tricuspid Atresia	451
General Considerations	451
Clinical Findings	452
Symptoms & Signs	452
Diagnostic Studies	452
Prognosis & Treatment	453
Pulmonary Atresia with Intact	
Ventricular Septum	453
General Considerations	453
Clinical Findings	453
Prognosis & Treatment	454
Other Cyanotic Congenital Heart Defects	454
Palliative Surgical Procedures	454
Arrhythmias in Congenital Heart Disease	455
Prevention of Infective Endocarditis	455
Genetic Counseling & Pregnancy	456
Recommendations for Exercise & Sports	
Participation	456
Acquired Heart Disease in Adults	
with Congenital Heart Disease	456

Section VI. Systemic Disease & the Heart

32. Cardiac Tumors 459

<i>Bill P.C. Hsieh, MD & Rita F. Redberg, MD, MSc</i>	
General Considerations	459
Metastatic Cardiac Tumors	459
Primary Tumors	459
Clinical Findings	465
Diagnostic Studies	466
Echocardiography	466
Computed Tomography	466
Magnetic Resonance Imaging	467
Positron Emission Tomography	468
Differential Diagnosis	468
Treatment	469
Pharmacologic Therapy	469
Radiation	470
Surgery	470
Cardiac Transplantation	470
Prognosis	470

Cardiac Toxicities from Oncologic Treatments	470
Chemotherapy	471
Radiation	473

33. Cardiovascular Disease in Pregnancy 474

<i>Kirsten Tolstrup, MD</i>	
General Considerations	474
Cardiovascular Physiology	
of Normal Pregnancy	474
Blood Volume	474
Cardiac Output	475
Blood Pressure and Vascular Resistance	475
Etiology & Symptomatology	476
Congenital Heart Disease	476
Valvular Heart Disease	479
Myocarditis	481
Cardiomyopathy	482
Coronary Artery Disease	483
Arrhythmias	484
Pericardial Diseases	486
Pulmonary Hypertension	486
Diseases of the Aorta	487
Hypertension	488
Clinical Findings	488
History	488
Symptoms & Signs	488
Physical Examination	488
Diagnostic Difficulties	488
Diagnostic Studies	489
Treatment	490
Pharmacologic Treatment	490
Surgical Treatment	493
Labor & Delivery	493
Prognosis	493

34. Endocrinology & the Heart 494

<i>Eveline Oestreicher Stock, MD</i>	
Thyroid & the Heart	494
Cardiovascular Effects	
of Thyroid Hormones	494
Hyperthyroidism	495
General Considerations	495
Clinical Findings	495
History	495
Symptoms & Signs	495
Diagnostic Studies	497
Treatment	498
Prognosis	499
Hypothyroidism	499
General Considerations	499
Clinical Findings	500
Symptoms & Signs	500

Physical Examination	500
Diagnostic Studies	500
Treatment	500
Prognosis	501
Effect of Heart Disease on Thyroid Function	502
Cardiovascular Drugs & the Thyroid	502
Parathyroid & the Heart	503
Hyperparathyroidism	503
General Considerations	503
Clinical Findings	503
Symptoms & Signs	503
Physical Examination	504
Diagnostic Studies	504
Treatment & Prognosis	504
Hypoparathyroidism	505
Adrenal & the Heart	505
Pheochromocytoma	505
General Considerations	505
Clinical Findings	505
Symptoms & Signs	505
Physical Examination	506
Diagnostic Studies	506
Treatment	507
Prognosis	507
Adrenal Insufficiency	508
General Considerations	508
Clinical Findings	508
Symptoms & Signs	508
Physical Examination	509
Diagnostic Studies	509
Treatment	509
Cushing Syndrome	509
General Considerations	509
Diagnostic Considerations	509
Treatment	510
Primary Hyperaldosteronism	510
General Considerations	510
Diagnostic Considerations	510
Treatment	511
Acromegaly & the Heart	511
General Considerations	511
Clinical Findings	511
Symptoms & Signs	511
Physical Examination	512
Diagnostic Studies	512
Treatment	512
Growth Hormone Deficiency	512
Carcinoid Tumors & the Heart	513
General Considerations	513
Treatment	513
Diabetes Mellitus & the Heart	513
General Considerations	513
Clinical Findings	514
Treatment	514

Effects of Diabetes on Peripheral Vascular Disease	516
Estrogens & the Heart	516
Hormone Replacement Therapy	516
Oral Contraceptives	517

35. Connective Tissue Diseases & the Heart 518

Carlos A. Roldan, MD

Systemic Lupus Erythematosus	518
General Considerations	518
Valvular Heart Disease	519
General Considerations	519
Valve Vegetations, or Libman-Sacks Endocarditis	519
Valve Thickening	519
Valve Regurgitation	520
Clinical Findings	520
Symptoms & Signs	520
Physical Examination	520
Diagnostic Studies	520
Treatment	521
Specific Anti-inflammatory Therapy	521
Long-Term Anticoagulation	521
Other Therapy	521
Pericarditis	521
General Considerations	521
Clinical Findings	521
Symptoms & Signs	521
Laboratory Findings	521
Diagnostic Studies	522
Treatment	522
Medical Therapy	522
Surgical Therapy	522
Myocarditis or Cardiomyopathy	522
General Considerations	522
Clinical Findings	522
Symptoms & Signs	522
Diagnostic Studies	523
Treatment	523
Specific Anti-inflammatory Therapy	523
Other Therapy	523
Thrombotic Diseases	523
General Considerations	523
Clinical Findings	523
Symptoms & Signs	523
Laboratory Findings	523
Diagnostic Studies	524
Treatment	524
Specific Anti-inflammatory Therapy	524
Other Therapy	524
Coronary Artery Disease	524
General Considerations	524

Clinical Findings	524	Coronary Artery Disease	532
Symptoms & Signs	524	Pathophysiology	532
Diagnostic Studies	524	Clinical Findings	533
Treatment	525	Symptoms & Signs	533
Specific Anti-inflammatory Therapy	525	Diagnostic Studies	533
Other Therapy	525	Treatment	533
Cardiac Arrhythmias & Conduction		Myocarditis	533
Disturbances	525	General Considerations	533
General Considerations	525	Clinical Findings	534
Treatment	525	Symptoms & Signs	534
Specific Anti-inflammatory Therapy	525	Diagnostic Studies	534
Other Therapy	525	Treatment	535
Prognosis	525	Prognosis	535
Rheumatoid Arthritis	526	Conduction Disturbances & Arrhythmias	535
General Considerations	526	General Considerations	535
Rheumatoid Pericarditis	526	Clinical Findings	535
Clinical Findings	526	Symptoms & Signs	535
Symptoms & Signs	526	Diagnostic Studies	535
Laboratory Findings	526	Treatment	535
Diagnostic Studies	526	Prognosis	535
Treatment	527	Pericarditis	535
Prognosis	527	General Considerations	535
Rheumatoid Valvular Heart Disease	527	Clinical Findings	535
General Considerations	527	Symptoms & Signs	535
Clinical Findings	527	Diagnostic Studies	536
Physical Examination	527	Treatment	536
Diagnostic Studies	527	Prognosis	536
Treatment	528	Valvular Heart Disease	536
Rheumatoid Myocarditis	528	Secondary Scleroderma Heart Disease	536
General Considerations	528	Ankylosing Spondylitis	537
Clinical Findings	529	General Considerations	537
Physical Examination	529	Aortitis & Aortic Regurgitation	537
Laboratory Findings	529	General Considerations	537
Diagnostic Studies	529	Clinical Findings	538
Treatment & Prognosis	529	Physical Examination	538
Rheumatoid Coronary Artery Disease	529	Diagnostic Studies	538
General Considerations	529	Treatment	538
Clinical Findings	530	Medical Therapy	538
Symptoms & Signs	530	Surgical Therapy	538
Diagnostic Studies	530	Conduction Disturbances	538
Treatment	530	Clinical Findings	538
Conduction Disturbances & Arrhythmias	531	Physical Examination	539
General Considerations	531	Diagnostic Studies	539
Clinical Findings	531	Treatment	539
Symptoms & Signs	531	Specific Anti-inflammatory Therapy	539
Diagnostic Studies	531	Other Therapy	539
Treatment	531	Mitral Valve Disease	539
Rheumatoid Pulmonary Hypertension	531	Myocardial Disease, Coronary Artery Disease,	
General Considerations	531	Pericardial Disease, & Bacterial Endocarditis	539
Clinical Findings	531	Prognosis	540
Symptoms & Signs	531	Polymyositis/Dermatomyositis	540
Diagnostic Studies	531	General Considerations	540
Treatment & Prognosis	532	Clinical Findings	540
Scleroderma	532	Myocarditis	541
General Considerations	532	Arrhythmias & Conduction Disturbances	541

Coronary Arteritis	541
Valvular Heart Disease	541
Pericarditis	541
Pulmonary Hypertension, Cor Pulmonale, & Hyperkinetic Heart Syndrome	541
Treatment & Prognosis	541
Mixed Connective Tissue Disease	542
General Considerations	542
Clinical Findings	542
Symptoms & Signs	542
Diagnostic Studies	542
Treatment	542
Prognosis	543

36. The Athlete and the Heart 544

*Antonio B. Fernandez, MD &
Paul D. Thompson, MD*

General Considerations	544
Physiology of Exercise Training	544
Chamber Morphologic Adaptations to Endurance Training	545
Sudden Cardiac Death in Athletes	545
Clinical Findings	546
Medical History & Physical Examination	546
Diagnostic Studies	547
Integrating the Clinical Findings in Evaluating Athletes	548
Preparticipation Screening	549
Recommendations for Sport Participation	549

37. Thoracic Aortic Aneurysms & Dissections 550

John A. Elefteriades, MD

Aneurysms	550
General Considerations	550
Etiology	550
Clinical Findings	555
Natural History	555
Symptoms & Signs	558
Physical Examination	558
Diagnostic Studies	558
Treatment	558
Risks of Aortic Surgery	558
Indications & Contraindications	558
Surgical Techniques	560
Specific Clinical Scenarios & Issues	561
Aortic Dissection	563
General Considerations	564
Terminology	564
Anatomic Classification	565
Clinical Findings	565
Symptoms & Signs	565
Diagnostic Studies	566
Differential Diagnosis	567
Treatment	567
Pharmacotherapy	567
Surgical Treatment	568
Prognosis	568

Index 571